JP2013533278A - ジミラセタムの製造方法 - Google Patents
ジミラセタムの製造方法 Download PDFInfo
- Publication number
- JP2013533278A JP2013533278A JP2013521097A JP2013521097A JP2013533278A JP 2013533278 A JP2013533278 A JP 2013533278A JP 2013521097 A JP2013521097 A JP 2013521097A JP 2013521097 A JP2013521097 A JP 2013521097A JP 2013533278 A JP2013533278 A JP 2013533278A
- Authority
- JP
- Japan
- Prior art keywords
- glycinamide
- reaction
- hours
- process according
- acid ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XTXXOHPHLNROBN-UHFFFAOYSA-N dimiracetam Chemical compound N1C(=O)CN2C1CCC2=O XTXXOHPHLNROBN-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229950002911 dimiracetam Drugs 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 32
- UIUJIQZEACWQSV-UHFFFAOYSA-N 4-Oxobutanoic acid Natural products OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000243 solution Substances 0.000 claims abstract description 18
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- -1 4-oxobutanoic acid ester Chemical class 0.000 claims abstract description 10
- 238000005580 one pot reaction Methods 0.000 claims abstract description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 229910021529 ammonia Inorganic materials 0.000 claims description 9
- 229960004592 isopropanol Drugs 0.000 claims description 9
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical group Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 6
- QFMPHCGACBODIJ-UHFFFAOYSA-N ethyl 4-oxobutanoate Chemical compound CCOC(=O)CCC=O QFMPHCGACBODIJ-UHFFFAOYSA-N 0.000 claims description 5
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 239000002585 base Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001299 aldehydes Chemical group 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- AAFMVGHJBLBRHQ-UHFFFAOYSA-N 2-methylpropyl 4-oxobutanoate Chemical compound CC(C)COC(=O)CCC=O AAFMVGHJBLBRHQ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 2
- GGBQSAFVNVHRDZ-UHFFFAOYSA-N ethyl 3-(4-oxoimidazolidin-2-yl)propanoate Chemical compound CCOC(=O)CCC1NCC(=O)N1 GGBQSAFVNVHRDZ-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960001227 oxiracetam Drugs 0.000 description 2
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- LNSPMOHJLXEULR-UHFFFAOYSA-N 2-ethyl-4-oxobutanoic acid Chemical compound CCC(C(O)=O)CC=O LNSPMOHJLXEULR-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- ZXRWQRYMEYRQKX-UHFFFAOYSA-N 5-ethoxypyrrolidin-2-one Chemical compound CCOC1CCC(=O)N1 ZXRWQRYMEYRQKX-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- IJLHJPJKROXXIU-UHFFFAOYSA-N O=C1NC(NC1)C(C(=O)O)CC Chemical compound O=C1NC(NC1)C(C(=O)O)CC IJLHJPJKROXXIU-UHFFFAOYSA-N 0.000 description 1
- DWQYDOKBAHHBLC-UHFFFAOYSA-N OC(=O)CCC1NCC(=O)N1 Chemical compound OC(=O)CCC1NCC(=O)N1 DWQYDOKBAHHBLC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical compound [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 230000003496 anti-amnesic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- ZADFVOHZFLYHOB-UHFFFAOYSA-N benzyl n-(5-oxopyrrolidin-2-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCC(=O)N1 ZADFVOHZFLYHOB-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- GVONPBONFIJAHJ-UHFFFAOYSA-N imidazolidin-4-one Chemical compound O=C1CNCN1 GVONPBONFIJAHJ-UHFFFAOYSA-N 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
本発明は、ジミラセタムの新規な製造方法であって、この化合物を高純度及び良好な収率で与える方法に関する。
WO 93/09120は、ジミラセタム(2,5−ジオキソヘキサヒドロ−1H−ピロロ[1,2−a]イミダゾール)(1)及び関連する化合物の製造方法を記載する。5−エトキシ−2−ピロリドンを、触媒量のp−トルエンスルホン酸でカルバミン酸ベンジルと反応させることにより、5−ベンジルオキシカルボニルアミノ−2−ピロリドンが得られる。この化合物を次に、アセトニトリル中の水素化ナトリウムによりピロリジン窒素で脱プロトン化し、そしてブロモ酢酸エチルと反応させることにより、5−ベンジルオキシカルボニルアミノ−2−オキソ−1−ピロリジン−酢酸エチル(2)が得られる。次いで種々の環化剤の存在下で、エチルエステル及び/又はベンジルオキシカルボニル保護基の開裂を経て環化が実行できる。
本発明は、4−オキソブタン酸エステル(I)(ここで、Rは、低級アルキルである)をグリシンアミド(II)又はその酸付加塩とpHを制御したワンポット反応で縮合することを特徴とする、ジミラセタム(1)の合成法に関する。本反応は、水溶液中又は無水低級アルコール溶液中で実行してもよい。
本発明は、4−オキソ−ブタン酸エステル(I)をグリシンアミド(II)又はその酸付加塩とpHを制御したワンポット反応で縮合することを特徴とする、ジミラセタムの合成のための新規の効率的プロセスに関する。
実施例1
水溶液中での調製
水200ml中のグリシンアミド塩酸塩(純度98%)2.56g(22.7mmol)の溶液を95℃に加熱して、水中のNa2CO3 20%(w/v)でpHを6.6に調整した。次に4−オキソブタン酸エチル(純度97%)(7.60g、56.6mmol)を4時間にわたって滴下により加え、その間、温度を95℃で、水中のNa2CO3 20%(w/v)の自動添加(pHスタット)によりpHを6.6に維持した。この溶液を95℃で1.5時間撹拌し、次に真空下で少容量に濃縮した。得られた懸濁液は、イソプロパノール50mlで処理して、大気圧で溶媒を留去した。この操作をもう1度繰り返した。残渣をイソプロパノール50mlで希釈して、生じる懸濁液を60℃に加熱し、次に濾過した。濾液を約15mlまで濃縮し、室温に冷却して、撹拌を約2時間続けた。白色の沈殿物を吸引濾過により集め、イソプロパノール4mlで洗浄して60℃で12時間真空乾燥することにより、粗ジミラセタム1.8g(12.8mmol、55.5%)を得た。イソプロパノール(10容量)からの再結晶により、純粋なジミラセタム(面積%HPLCから測定したとき>99.5%)1.6g(50%)を得た。
融点:154℃
1H−NMR(CD3OD中):1.90-2.05 (1H, m), 2.33-2.44 (1H, m), 2.48-2.60 (1H, m), 2.64-2.78 (1H, m), 3.55 及び 4.02 (2H, AB q, J=15.9 Hz), 4.76 (s, H20), 5.34 (1H, t, J=6.12 Hz).
13C−NMR(CD3OD):30.8 (CH2), 32.4 (CH2), 47.7 (CH2), 74.0 (CH), 175.2 (C=0), 180.1 (C=0).
FT−IR:3280 cm-1 (NH), 1678-1698 cm-1 (C=0), 1222-1284 cm-1.
MS:m/z 141 (MH+).
HPLC条件:カラム:Zorbax SB-AQ、250mm×4.6mm×5mm;検出:UV 200nm;移動相A:HPLCグレード水;移動相B:アセトニトリル/水(50:50)。
n−プロパノール中での調製
n−プロパノール7.2リットル中のグリシンアミド塩酸塩(純度98%)90.0g(0.798mol)の懸濁液を加熱還流して、溶媒250mlを留去した。n−プロパノール中のナトリウムtert−ブトキシドの15%(w/v)溶液(260ml、0.35mol)を加えて、5.5の見かけpHを測定した。n−プロパノール中のナトリウムtert−ブトキシドの15%(w/v)溶液の自動添加により、この5.5の見かけpHを維持しながら、4−オキソブタン酸エチル(純度97%)(262.3g、1.955mol)を4時間にわたって滴下により加えるが、その間、反応混合物を還流温度に保持し、約400ml/時で溶媒を連続蒸留し、そして約400ml/時で反応混合物にn−プロパノールを連続添加した。n−プロパノール中のナトリウムtert−ブトキシド15%(w/v)溶液を総量363ml(0.476mol)加える。この混合物を還流温度で更に1.5時間撹拌し、次に65℃に冷却した。n−プロパノール中のアンモニアの7.5%(w/w)溶液(800g)をこの混合物に6時間にわたりゆっくり加え、65℃での加熱を更に18時間続けた。反応混合物を室温に冷却して、沈殿物を濾別した。この清澄な溶液を少容量(約0.5リットル)まで真空下で濃縮して、0℃で2時間撹拌した。吸引濾過により白色の沈殿物を集め、n−プロパノール50mlで洗浄して60℃で12時間真空乾燥することにより、融点154℃の純粋なジミラセタム(65g、58.1%)を得た。HPLC純度:99.7%。
Claims (15)
- 4−オキソ−ブタン酸エステル(I)をグリシンアミド(II)又はその酸付加塩と水溶液中で縮合する、請求項1に記載の方法。
- 4−オキソ−ブタン酸エステル(I)をグリシンアミド(II)又はその酸付加塩と無水低級アルコール溶液中で縮合する、請求項1に記載の方法。
- 4−オキソ−ブタン酸エステル(I)が、4−オキソブタン酸エチルである、請求項1〜3のいずれか1項に記載の方法。
- グリシンアミド(II)酸付加塩が、グリシンアミド塩酸塩である、請求項1〜4のいずれか1項に記載の方法。
- pHが、pH5.5〜7.5の範囲内に保持される、請求項2、4又は5に記載の方法。
- 反応温度が、およそ100℃で0.5〜10時間保持される、請求項2、4、5又は6のいずれか1項に記載の方法。
- 反応温度が、およそ100℃で1〜3時間保持される、請求項7に記載の方法。
- 1モル当量のグリシンアミド(II)に対して1〜3モル当量の4−オキソブタン酸エステル(I)が使用される、請求項2、4、5、6、7又は8のいずれか1項に記載の方法。
- 低級アルコールが、メタノール、エタノール、n−プロパノール、イソ−プロパノール、n−ブタノール、sec−ブタノール、イソ−ブタノール、tert−ブタノール、n−ペンタノール及びイソ−ペンタノールよりなる群から選択される、請求項3、4又は5に記載の方法。
- 低級アルコールが、n−プロパノールである、請求項10に記載の方法。
- 反応の最終段階でアンモニアが添加される、請求項3、4、5、10又は11のいずれか1項に記載の方法。
- 反応温度が90〜120℃で2〜10時間保持される、請求項3、4、5、10、11又は12のいずれか1項に記載の方法。
- アンモニアの添加後の反応温度が、30〜90℃で10〜24時間保持される、請求項12に記載の方法。
- アンモニアの添加後の反応温度が、60〜70℃で16〜20時間保持される、請求項12に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170741.2 | 2010-07-26 | ||
EP10170741 | 2010-07-26 | ||
PCT/EP2011/062767 WO2012013640A1 (en) | 2010-07-26 | 2011-07-25 | Process for the preparation of dimiracetam |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013533278A true JP2013533278A (ja) | 2013-08-22 |
JP5919270B2 JP5919270B2 (ja) | 2016-05-18 |
Family
ID=43066948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013521097A Expired - Fee Related JP5919270B2 (ja) | 2010-07-26 | 2011-07-25 | ジミラセタムの製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8476453B2 (ja) |
EP (1) | EP2598504B1 (ja) |
JP (1) | JP5919270B2 (ja) |
KR (1) | KR101896349B1 (ja) |
CN (1) | CN103052638B (ja) |
ES (1) | ES2473271T3 (ja) |
PL (1) | PL2598504T3 (ja) |
PT (1) | PT2598504E (ja) |
WO (1) | WO2012013640A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190251A1 (ar) | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01246281A (ja) * | 1988-02-08 | 1989-10-02 | Isf Spa | 向精神性作用化合物及びその調製法 |
WO1993009120A1 (en) * | 1991-11-07 | 1993-05-13 | Smithkline Beecham Farmaceutici S.P.A. | Process for the preparation of condensed imidazoles |
JP2006523198A (ja) * | 2003-03-24 | 2006-10-12 | ニケム・リサーチ・ソシエタ・ア・レスポンサビリタ・リミタータ | 向知性作用を有する化合物、その調製方法、これを有する薬学的組成物、及びその使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20070770A1 (it) * | 2007-04-16 | 2008-10-17 | Brane Discovery S R L | Impiego di dimiracetam nel trattamento del dolore cronico |
US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
KR101803351B1 (ko) * | 2013-06-24 | 2017-12-28 | (주)휴럼 | 항산화효능을 가지는 까마귀쪽나무 열매의 정유성분으로 이루어진 조성물 |
-
2011
- 2011-07-25 PL PL11736359T patent/PL2598504T3/pl unknown
- 2011-07-25 JP JP2013521097A patent/JP5919270B2/ja not_active Expired - Fee Related
- 2011-07-25 PT PT117363598T patent/PT2598504E/pt unknown
- 2011-07-25 ES ES11736359.8T patent/ES2473271T3/es active Active
- 2011-07-25 US US13/811,727 patent/US8476453B2/en active Active
- 2011-07-25 CN CN201180036551.8A patent/CN103052638B/zh not_active Expired - Fee Related
- 2011-07-25 EP EP11736359.8A patent/EP2598504B1/en active Active
- 2011-07-25 WO PCT/EP2011/062767 patent/WO2012013640A1/en active Application Filing
- 2011-07-25 KR KR1020137004650A patent/KR101896349B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01246281A (ja) * | 1988-02-08 | 1989-10-02 | Isf Spa | 向精神性作用化合物及びその調製法 |
EP0335483A2 (en) * | 1988-02-08 | 1989-10-04 | Isf Societa Per Azioni | Condensed imidazole derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them. |
WO1993009120A1 (en) * | 1991-11-07 | 1993-05-13 | Smithkline Beecham Farmaceutici S.P.A. | Process for the preparation of condensed imidazoles |
JP2006523198A (ja) * | 2003-03-24 | 2006-10-12 | ニケム・リサーチ・ソシエタ・ア・レスポンサビリタ・リミタータ | 向知性作用を有する化合物、その調製方法、これを有する薬学的組成物、及びその使用 |
Non-Patent Citations (2)
Title |
---|
JPN5006003559; MARIO PINZA: JOURNAL OF MEDICINAL CHEMISTRY Vol.36, No.26, 19931224, pp.4214-4220 * |
JPN6015022185; FARINA,C. et al: BIOORGANIC AND MEDICINAL CHEMISTRY Vol.16, 2008, pp.3224-3232 * |
Also Published As
Publication number | Publication date |
---|---|
US8476453B2 (en) | 2013-07-02 |
KR20140019280A (ko) | 2014-02-14 |
US20130123509A1 (en) | 2013-05-16 |
ES2473271T3 (es) | 2014-07-04 |
PT2598504E (pt) | 2014-07-14 |
WO2012013640A1 (en) | 2012-02-02 |
JP5919270B2 (ja) | 2016-05-18 |
KR101896349B1 (ko) | 2018-09-07 |
EP2598504A1 (en) | 2013-06-05 |
PL2598504T3 (pl) | 2014-10-31 |
EP2598504B1 (en) | 2014-04-16 |
CN103052638B (zh) | 2015-09-30 |
CN103052638A (zh) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2794610B1 (en) | Processes and intermediates for preparing pralatrexate | |
US20150183789A1 (en) | Improved process for the preparation of pralatrexate | |
EP2238118A1 (en) | Method of synthesis of bosentan, its polymorphic forms and its salts | |
EP3464237B1 (en) | Novel process for the preparation of gadolinium complex of (4s)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9- triazaundecanedioic acid disodium (gadoxetate disodium) | |
JP5919270B2 (ja) | ジミラセタムの製造方法 | |
US20090171084A1 (en) | Production method of aminopyrimidine compound | |
US6803467B2 (en) | Intermediates for the production of quinolone carboxylic acid derivatives | |
US6797828B1 (en) | Processes for the preparation of 4(5)-amino-5(4)-carboxamidoimidazoles and intermediates thereof | |
WO2008059512A1 (en) | Process for preparation of prulifloxacin using novel intermediates | |
US20050176961A1 (en) | Process for production of naphthyridine-3-carboxylic acid derivatives | |
JP2001511808A (ja) | エプロサルタンの製造方法 | |
US8093384B2 (en) | Processes for the preparation of alfuzosin | |
KR20020019895A (ko) | [S-(R*,S*)-β-[[[1-[1-옥소-3-(4-피페리디닐)프로필]-3-피페리디닐]카보닐]아미노]-3-피리딘 프로판산 및유도체의 제조방법 | |
US20080096946A1 (en) | Process For The Preparation Of Anastrozole | |
US20120165527A1 (en) | process for the preparation of pure paliperidone | |
US7223882B2 (en) | Process for producing triterpene derivative | |
KR20200088570A (ko) | 피마살탄 및 그의 제조 중간체의 제조방법 | |
US11858901B2 (en) | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | |
KR100432577B1 (ko) | 이미다졸 유도체의 제조방법 | |
JP3719269B2 (ja) | 2−アルキル−4−オキソ−5、6、7、8−テトラヒドロ−シクロヘプトイミダゾールの製造方法 | |
AU2010280358A1 (en) | Processes for the preparation of vardenafil | |
CN116867789A (zh) | 一种伊喜替康衍生物的制备方法及其中间体 | |
US20030096994A1 (en) | Method for producing thienopyrimidines | |
MX2013014350A (es) | Compuestos de fenilo sustituidos. | |
KR20110094751A (ko) | 텔미사탄의 개선된 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140709 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150306 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150826 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160202 |
|
R155 | Notification before disposition of declining of application |
Free format text: JAPANESE INTERMEDIATE CODE: R155 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160411 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5919270 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |